October Pharma results, Q2 2024
Net profit, assets, equity and cash flow for Q2 2024, against the same period a year earlier, from the published financial statements.
Net profit152 millionEGP · −16.6% vs the same period a year earlier
Total assets1.41 billionEGP · +24.2% vs the same period a year earlier
Shareholders' equity569 millionEGP · −3.4% vs the same period a year earlier
Operating cash flow43.24 millionEGP · −71.7% vs the same period a year earlier
In short
- October Pharma's net profit for Q2 2024 was about 152 million EGP, down −16.6% from 182 million EGP in Q2 2023.
- Total assets at the end of Q2 2024 were about 1.41 billion EGP, and shareholders' equity about 569 million EGP.
- Operating cash flow for Q2 2024 was positive at 43.24 million EGP.
Key lines against the same period a year earlier
This periodQ2 2023Change
Net profit152 million182 million−16.6%
Gross profit546 million511 million+6.9%
Total assets1.41 billion1.14 billion+24.2%
Total liabilities844 million549 million+53.9%
Shareholders' equity569 million590 million−3.4%
Total liabilities and equity1.41 billion1.14 billion+24.2%
Operating cash flow43.24 million153 million−71.7%
Investing cash flow-48.94 million-35.4 million−38.3%
Financing cash flow12.94 million-79.09 million+116.4%
Net change in cash7.23 million38.38 million−81.2%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
October Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy